- Amazon One Medical launched a new weight management program that includes access to GLP-1 medications for eligible members.
- Compounded GLP-1 pills start at $25 per month, dramatically undercutting branded drugs like Ozempic and Wegovy.
- Same-day delivery of medications is available in approximately 3,000 cities through Amazon’s pharmacy and logistics network.
- The program combines virtual care visits, prescriptions, and ongoing support — positioning Amazon as a vertically integrated obesity care provider.
What Happened?
Amazon One Medical has officially launched a comprehensive weight management program, offering patients access to GLP-1 receptor agonist medications — the same drug class behind blockbusters like Ozempic and Wegovy. The program features compounded GLP-1 pills starting at just $25 per month, pairing affordability with Amazon’s massive delivery infrastructure to offer same-day medication access in around 3,000 U.S. cities. Members receive virtual clinical consultations, personalized prescriptions, and ongoing monitoring through the One Medical platform.
Why It Matters?
GLP-1 drugs have transformed the obesity treatment landscape, but their headline prices — often $800–$1,300 per month — have kept them out of reach for millions of Americans. Amazon’s entry into this market with compounded alternatives at a fraction of the cost threatens to disrupt the pricing power of pharma giants like Novo Nordisk and Eli Lilly. More broadly, it demonstrates Amazon’s ambition to become a full-stack healthcare provider — combining primary care, pharmacy, and last-mile delivery into a single seamless experience that legacy health systems cannot match.
What’s Next?
Amazon is expected to aggressively market the program to its Prime subscriber base, which could rapidly scale enrollment. The move will intensify competition in the direct-to-consumer GLP-1 space, where startups like Hims & Hers and Ro already operate. Regulators and branded drug manufacturers will be watching closely, as compounded GLP-1 availability remains a legally contested area following FDA scrutiny of compounding pharmacies. The program’s expansion could also pressure traditional insurers and employers to revisit their own obesity drug coverage policies.
Source: Healthcare Dive
